Contact Us | Directions | Referring a Patient

A leading comprehensive brain tumor program, using molecular diagnostic, gene expression analysis,
cutting edge clinical trials and advanced medical informatics to customize treatment plans for cancer patients.
 Latest Headlines
•American Brain Tumor Association Names Student Research Award Winner
Tue, 31 Jan 2012 09:52:37 -0800
•The Florida Brain Tumor Association Announces a $600,000 Gift for the Advancement of Pediatric Brain Cancer Research
Mon, 30 Jan 2012 04:03:03 -0800
•American Brain Tumor Association Announces “Breakthrough for Brain Tumors” 5K Event
Thu, 02 Feb 2012 09:46:57 -0800
•Baby born with rare brain tumor faces chemo
Fri, 10 Feb 2012 10:38:55 -0800
•Henry Ford Hospital: First in U.S. to Start New Clinical Trial For Innovative Treatment Under Investigation for ...
Tue, 31 Jan 2012 08:39:00 -0800
•Candlelight vigil to support 9-year-old battling a brain tumor
Fri, 10 Feb 2012 20:43:32 -0800
•Brain Tumor Gene Mutations Discovered in Early Childhood Cases
Wed, 01 Feb 2012 08:20:49 -0800
•Benefit raises $22,000 for 10 year old with brain tumor
Sat, 11 Feb 2012 17:55:25 -0800
•Diagnostic brain tumor test could revolutionize care of patients
Fri, 27 Jan 2012 06:48:56 -0800
•UF receives $10M donation to study brain tumor causes
Mon, 30 Jan 2012 14:41:44 -0800

* Headlines are from industry sponsored news wires, medical journals and established news organizations from around the world . Please consider the source of the content when viewing the story.
   
 
Dani Saleh Brain Cancer Research Fund at UCLA


The Dani Saleh Brain Cancer Research Fund supports the brain cancer research collaboration between Dr. Timothy Cloughesy and Dr. Stan Nelson. This fund will directly support the work and training of a research fellow in Dr. Stan Nelson’s lab.

Dr. Nelson is Professor and Vice Chair of Human Genetics and Professor of Psychiatry at the David Geffen School of Medicine at UCLA.


Improving clinical outcomes in glioblastoma brain tumors with genetic analysis

In this study, featured in the New England Journal of Medicine, glioblastomas patients who were treated with gefitinib or erlotinib, were found to be responsive to EGFR kinase inhibitors and strongly associated with coexpression by the tumor of EGFRvIII and PTEN.



UCLA Neuro-Oncology & SiliconMED Launch Online Tool Correlating Gene Expression Levels with Overall Survival of Brain Cancer Patients

Genomic analysis is a powerful new tool permitting unprecedented insights into how brain tumors form and has been enabled primarily through microarray technology. ProbeSetAnalyzer.com, a new web based tool, is aiming to help clinicians and researchers take the massive amount of data created by microarrays and better visualize gene expression levels and how they relate to the overall survival of brain cancer patients.

Most Popular
. Clinical Trials
. Probe Set Analyzer
. Our Team
. Brain Tumor Translational Resource
. Art of the Brain
. Personalized Medicine using Targeted Molecular Therapy
. Online Giving
. How our Glioblastoma Multiforme Patients Perform
Neuro-Oncology on Facebook

Spring / Summer 2011
Breakthroughs



It is time to include patients with brain tumors in phase I trials in oncology.
J Clin Oncol.


Graded functional diffusion map-defined characteristics of apparent diffusion coefficients predict overall survival in recurrent glioblastoma treated with bevacizumab.
Neuro Oncol.


Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma.
Neuro Oncol.


Cilengitide in patients with recurrent glioblastoma: the results of NABTC 03-02, a phase II trial with measures of treatment delivery.
J Neurooncol.


Phase II study of aflibercept in recurrent malignant glioma: a north american brain tumor consortium study.
J Clin Oncol.

All Information content hearof is designed for educational purposes only and is not for the purpose of rendering medical advice or professional services. The information provided should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. Any specific questions you may have regarding an individual's medical condition should be directed to the individual's primary care physician or other attending physician. In addition, if you have or suspect you may have a health problem, you should consult your health care provider.

Portions Copyright (Search, Chart, Content Publishing Tools, Photography, ProviderIQ) 1998-2012 SiliconMED North America

ProviderIQ is a registered trademark of SiliconMED North America and used by permission.

Copyright © 2012 UCLA Neuro-Oncology Program | Timothly Cloughesy MD; Director
All Rights Reserved.

[Content Published:2/12/2012 7:49:16 AM PST]